Delcasertib

Drug Profile

Delcasertib

Alternative Names: BMS-875944; CS-9803; KAI-9803; KID1-1

Latest Information Update: 31 Jul 2015

Price : $50

At a glance

  • Originator KAI Pharmaceuticals
  • Class Cardiovascular therapies; Peptides
  • Mechanism of Action Protein kinase C delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Reperfusion injury; Stroke

Most Recent Events

  • 05 Jul 2012 KAI Pharmaceuticals has been acquired by Amgen
  • 30 Aug 2011 KAI Pharmaceuticals completes a phase IIb trial in Reperfusion injuries in Europe, North America, Israel, New Zealand, and Australia (NCT00785954)
  • 05 Apr 2011 Efficacy data from the phase II PROTECTION-AMI trial in Reperfusion injury presented at the 60th Annual Scientific Session of the American College of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top